X4 Pharmaceuticals Plans Phase 2b Mavorixafor Trial in Chronic Neutropenia for Q1 2027

• X4 Pharmaceuticals outlined a 15,000-patient U.S. market opportunity for mavorixafor in primary chronic neutropenia, potentially expanding to 30,000 patients, subject to FDA labeling.
• The Phase 3 4WARD trial remains on track to complete target enrollment of 126 participants in the fourth quarter of 2026.
• The planned Phase 2b 4STEPS trial will evaluate reducing G-CSF dosing with mavorixafor; enrollment is expected to begin in the first quarter of 2027.
• Topline results from both trials are expected in the first quarter of 2028.
• Positive 4WARD results could support a regulatory submission, with potential FDA approval in late 2028 or early 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291630PRIMZONEFULLFEED9856522) on October 29, 2026, and is solely responsible for the information contained therein.